Mifamurtide: a review of its use in the treatment of osteosarcoma (Q37756110)

22 August 2017

1 reference

title

Mifamurtide: a review of its use in the treatment of osteosarcoma (English)

1 reference

22 August 2017

James E Frampton

1

1 reference

22 August 2017

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

12

1 reference

22 August 2017

141-153

1 reference

22 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/11204910-000000000-00000

22 August 2017

0 references

cites work

Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma

1 reference

12 December 2020

Nano- or submicron-sized liposomes as carriers for drug delivery

1 reference

12 December 2020

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

1 reference

12 December 2020

Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes

1 reference

12 December 2020

Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma

1 reference

12 December 2020

Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer

1 reference

12 December 2020

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

1 reference

12 December 2020

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial

1 reference

12 December 2020

Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat.

1 reference

12 December 2020

Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes

1 reference

12 December 2020

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study

1 reference

12 December 2020

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

1 reference

12 December 2020

Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine

1 reference

12 December 2020

Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes

1 reference

12 December 2020

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma

1 reference

12 December 2020

Muramyl Tripeptide Phosphatidylethanolamine Encapsulated in Liposomes Stimulates Monocyte Production of Tumor Necrosis Factor and Interleukin-1 In Vitro

1 reference

12 December 2020

Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro

1 reference

12 December 2020

Osteosarcoma: the same old drugs or more?

1 reference

12 December 2020

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

1 reference

12 December 2020

Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation

1 reference

12 December 2020

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases

1 reference

12 December 2020

Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously

1 reference

12 December 2020

Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.

1 reference

12 December 2020

Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide

1 reference

12 December 2020

Interleukin-6 induction by a muramyltripeptide derivative in cancer patients

1 reference

12 December 2020

Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents

1 reference

12 December 2020

Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin

1 reference

12 December 2020

1 reference

12 December 2020

Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine

1 reference

12 December 2020

In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells

1 reference

12 December 2020

Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.

1 reference

12 December 2020

Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)

1 reference

12 December 2020

Osteosarcoma: current status of immunotherapy and future trends (Review).

1 reference

12 December 2020

Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides

1 reference

12 December 2020

Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells

1 reference

12 December 2020

Tumour-targeted nanomedicines: principles and practice.

1 reference

12 December 2020

In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells

1 reference

12 December 2020

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration

1 reference

12 December 2020

Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma

1 reference

12 December 2020

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?

1 reference

12 December 2020

Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma

1 reference

12 December 2020

Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy

1 reference

12 December 2020

Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide

1 reference

12 December 2020

Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells

1 reference

12 December 2020

Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide

1 reference

12 December 2020

Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes

1 reference

12 December 2020

Therapy for osteosarcoma: where do we go from here?

1 reference

12 December 2020

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma

1 reference

12 December 2020

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

1 reference

12 December 2020

Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients

1 reference

12 December 2020

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma

1 reference

12 December 2020

Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide

1 reference

12 December 2020

Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma

1 reference

12 December 2020

In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators.

1 reference

12 December 2020

Novel agents in development for pediatric sarcomas

1 reference

12 December 2020

Osteosarcoma (osteogenic sarcoma).

1 reference

12 December 2020

Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance

1 reference

12 December 2020

Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine

1 reference

12 December 2020

The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide

1 reference

12 December 2020

Complexities in interpretation of osteosarcoma clinical trial results.

1 reference

12 December 2020

Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.

1 reference

12 December 2020

10.2165/11204910-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20481644

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20481644